Combinatorial engineering of a gene therapy vector: Directed evolution of adeno-associated virus

Journal of Gene Medicine

Volumn 8, Issue 2, 2006, Pages 155-162

  Perabo, Luca ^a,c   Endell, Jan ^a,c   King, Susan ^b   Lux, Kerstin ^a   Goldnau, Daniela ^a,c   Hallek, Michael ^a,b,c   Büning, Hildegard ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

AAV vectors; Capsid modification; Combinatorial library; Directed evolution; Human gene therapy; Pre existing immunity

Indexed keywords

ADENOVIRUS VECTOR;

ARTICLE; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; DIRECTED MOLECULAR EVOLUTION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROCESS DESIGN; STRAIN IMPROVEMENT; VIRAL GENE THERAPY; VIROGENESIS; VIROLOGY; VIRUS CAPSID; VIRUS MUTANT;

AMINO ACID SEQUENCE; DEPENDOVIRUS; DIRECTED MOLECULAR EVOLUTION; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; IMMUNE TOLERANCE; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; MIRIDAE;

EID: 32844470411     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.849     Document Type: Article

References (31)

1. Pfeifer A, Verma IM. Virus vectors and their applications. In: Fields Virology, Knipe DM, et al. (eds). Lippincott Williams & Wilkins: Philadelphia, 2001; 469-491.
2. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7: 33-40.
3. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346-358.
4. Monahan PE, Samulski RJ. AAV vectors: is clinical success on the horizon? Gene Ther 2000; 7: 24-30.
5. Huttner NA, Girod A, Perabo L, et al. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther 2003; 10: 2139-2147.
6. Girod A, Ried MU, Wobus CE, et al. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat Med 1999; 5: 1052-1056.
7. Grifman M, Trepel M, Speece P, et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 2001; 3: 964-975.
8. Shi W, Arnold GS, Bartlett JS. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 2001; 12: 1697-1711.
9. Wu P, Xiao W, Conlon T, et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000; 74: 8635-8647.
10. Nicklin SA, Buening H, Dishart KL, et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 2001; 4: 174-181.
11. Xie Q, Bu W, Bhatia S, et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A 2002; 99: 10 405-10 410.
12. Neylon C. Chemical and biochemical strategies for the randomization of protein encoding DNA sequences: library construction methods for directed evolution. Nucleic Acids Res 2004; 32: 1448-1459.
13. Christians FC, Scapozza L, Crameri A, et al. Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling. Nat Biotechnol 1999; 17: 259-264.
14. Crameri A, Raillard SA, Bermudez E, Stemmer WP. DNA shuffling of a family of genes from diverse species accelerates directed evolution. Nature 1998; 391: 288-291.
15. Kolkman JA, Stemmer WP. Directed evolution of proteins by exon shuffling. Nat Biotechnol 2001; 19: 423-428.
16. Zhang JH, Dawes G, Stemmer WP. Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening. Proc Natl Acad Sci U S A 1997; 94: 4504-4509.
17. Crameri A, Whitehorn EA, Tate E, Stemmer WP. Improved green fluorescent protein by molecular evolution using DNA shuffling. Nat Biotechnol 1996; 14: 315-319.
18. Crameri A, Cwirla S, Stemmer WP. Construction and evolution of antibody-phage libraries by DNA shuffling. Nat Med 1996; 2: 100-102.
19. Stemmer WP. Rapid evolution of a protein in vitro by DNA shuffling. Nature 1994; 370: 389-391.
20. Perabo L, Buning H, Kofler DM, et al. In vitro selection of viral vectors with modified tropism: the adeno-associated virus display. Mol Ther 2003; 8: 151-157.
21. Muller OJ, Kaul F, Weitzman MD, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 2003; 21: 1040-1046.
22. Soong NW, Nomura L, Pekrun K, et al. Molecular breeding of viruses. Nat Genet 2000; 25: 436-439.
23. Powell SK, Kaloss MA, Pinkstaff A, et al. Breeding of retroviruses by DNA shuffling for improved stability and processing yields. Nat Biotechnol 2000; 18: 1279-1282.
24. Grimm D, Kern A, Pawlita M, et al. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther 1999; 6: 1322-1330.
25. Moskalenko M, Chen L, van Roey M, et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol 2000; 74: 1761-1766.
26. Chirmule N, Xiao W, Truneh A, et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999; 6: 1574-1583.
27. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999; 59: 406-411.
28. Xiao W, Chirmule N, Schnell MA, et al. Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors. Mol Ther 2000; 1: 323-329.
29. Fisher KJ, Jooss K, Alston J, et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 3: 306-312.
30. Rabinowitz JE, Xiao W, Samulski RJ. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 1999; 265: 274-285.
31. Wobus CE, Hugle-Dorr B, Girod A, et al. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J Virol 2000; 74: 9281-9293.